ACUT Accustem Sciences Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $281,014 | $138,324 |
| SG&A expense | $1.48M | $1.37M |
| Operating income | -$1.76M | -$1.51M |
| Pretax income | -$1.76M | -$1.51M |
| Net income | -$1.76M | -$1.51M |
| EBITDA | -$1.76M | -$1.50M |
| EPS (basic) | -0.12 | -0.13 |
| EPS (diluted) | -0.12 | -0.13 |
| Weighted avg. shares (diluted) | 15.23M | 11.44M |
| Balance sheet | ||
| Cash & equivalents | $13,929 | $5,046 |
| Current assets | $49,446 | $50,433 |
| PP&E, net | — | $418 |
| Total assets | $1.55M | $50,851 |
| Current liabilities | $4.95M | $3.36M |
| Total liabilities | $4.95M | $3.36M |
| Shareholders' equity | -$3.40M | -$3.31M |
| Shares outstanding | 16.07M | 12.10M |
| Cash flow statement | ||
| Operating cash flow | -$850,389 | -$664,066 |
| Financing cash flow | $859,271 | $647,632 |
| Depreciation & amortization | $418 | $3,630 |
| Stock-based compensation | $88,695 | $69,718 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.